Discover
ALGS
Aligos Therapeutics, Inc.
5.34
2 x 4.07
2 x 7.04
bid
ask
+
0.03
0.56%
2 @ 06:55 PM
5.45 +0.11 (2.06%)
| Ytd | -42.70% | |
| 1y | -47.70% |
5.28
day range
5.41
4.08
52 week range
13.30
| Open | 5.28 | Prev Close | 5.31 | Low | 5.28 | High | 5.41 | Mkt Cap | 33.35M |
| Vol | 9.06K | Avg Vol | 88.98K | EPS | -7.45 | P/E | N/A | Forward P/E | -3.30 |
| Beta | 2.12 | Short Ratio | 0.50 | Inst. Own | 48.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 5.87 | 200-d Avg | 6.59 | 1yr Est | 103.33 |
| Income Statement | |||
| Total Revenue | 27.78M | ||
| Revenues (USD) | 27.78M | ||
| Gross Profit | 27.78M | ||
| Operating Expenses | 29.67M | ||
| Research and Development Expense | 24.05M | ||
| Selling, General and Administrative Expense | 5.62M | ||
| Operating Income | -1.89M | ||
| Interest Expense | -221.00K | ||
| Income Tax Expense | 2.81M | ||
| Net Income | -1.50M | ||
| Net Income Common Stock | -1.50M | ||
| Net Income Common Stock (USD) | -1.50M | ||
| Consolidated Income | -1.50M | ||
| Earnings per Basic Share | -0.14 | ||
| Earnings per Basic Share (USD) | -0.14 | ||
| Earnings per Diluted Share | -0.14 | ||
| Earning Before Interest & Taxes (EBIT) | 1.09M | ||
| Earning Before Interest & Taxes (USD) | 1.09M | ||
| Weighted Average Shares | 10.43M | ||
| Weighted Average Shares Diluted | 10.43M | ||
| Balance Sheet | |||
| Cash and Equivalents | 30.42M | ||
| Cash and Equivalents (USD) | 30.42M | ||
| Trade and Non-Trade Receivables | 27.78M | ||
| Current Assets | 62.13M | ||
| Property, Plant & Equipment Net | 3.44M | ||
| Total Assets | 66.33M | ||
| Debt Current | 3.22M | ||
| Total Debt | 3.50M | ||
| Current Liabilities | 28.34M | ||
| Debt Non-Current | 288.00K | ||
| Total Liabilities | 34.44M | ||
| Accumulated Retained Earnings (Deficit) | -666.74M | ||
| Accumulated Other Comprehensive Income | 437.00K | ||
| Shareholders Equity | 31.88M | ||
| Shareholders Equity (USD) | 31.88M | ||
| Assets Non-Current | 4.20M | ||
| Total Debt (USD) | 3.50M | ||
| Liabilities Non-Current | 6.10M | ||
| Trade and Non-Trade Payables | 6.43M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 728.00K | ||
| Net Cash Flow from Financing | 220.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 269.00K | ||
| Capital Expenditure | -1000 | ||
| Issuance (Purchase) of Equity Shares | 236.00K | ||
| Issuance (Repayment) of Debt Securities | -16.00K | ||
| Net Cash Flow from Investing | 25.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 25.00M | ||
| Net Cash Flow from Operations | -24.95M | ||
| Share Based Compensation | 1.36M | ||